No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
UCBJY UCB S.A. UNSP ADR EACH REPR 0.5 ORD
- 75.472
- -0.408-0.54%
15min DelayClose Jul 3 13:00 ET
28.65BMarket Cap79.53P/E (TTM)
75.880High75.090Low21.96KVolume75.880Open75.880Pre Close1.66MTurnover0.01%Turnover Ratio79.53P/E (Static)379.55MShares76.67052wk High2.97P/B28.65BFloat Cap34.47352wk Low0.73Dividend TTM379.55MShs Float76.670Historical High0.96%Div YieldTTM1.04%Amplitude31.963Historical Low75.821Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
UCB SA's Dividend Analysis
UCB S.A. UNSP ADR EACH REPR 0.5 ORD To Go Ex-Dividend On April 26th, 2024 With 0.72481 USD Dividend Per Share
April 19th - $UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US)$ is trading ex-dividend on April 26th, 2024. Shareholders of record on April 29th, 2024 will receive 0.72481 USD dividend per share on M
Ariceum Therapeutics to Present New Radioligand Therapy Data at American Association for Cancer Research (AACR) Annual Meeting 2024
BERLIN, April 4, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancer
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental
FDA Approves UCB's Bimzelx for Plaque Psoriasis
UCB Presents Late-breaking Posters at Child Neurology Society Meeting
ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of
Comments
Does anyone else think of investing in this way? See what good news might move the markets that day, invest in a bunch of companies, treat it like a portfolio. Trying this today with $Drug Manufacturers - General(LIST2428.US$ stocks:
$Pfizer(PFE.US$Plaxovid results against omicron may push it up
$EQRx(EQRX.US$Meeting phase III endpoints for sugemabalib
$AstraZeneca(AZN.US$Details of the HIMALAYA study showing 22% OS benefit in liver cancer
$UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US$Bimzelx achiev...
$Pfizer(PFE.US$Plaxovid results against omicron may push it up
$EQRx(EQRX.US$Meeting phase III endpoints for sugemabalib
$AstraZeneca(AZN.US$Details of the HIMALAYA study showing 22% OS benefit in liver cancer
$UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US$Bimzelx achiev...
1
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
bic mutney : buy more
Dafydd GreenOP : Might test the theory and see if it works… The market moves in mysterious ways, Cardiff Oncology (CRDF) had great data out yesterday and slumped, never quite know how markets take this kind of news (e.g. maybe people are looking at the data and thinking “well it’s good but it’s not great”)
Dafydd GreenOP : Eventually $Atara Biotherapeutics (ATRA.US)$ went up 2.08% but the worst was $EQRx (EQRX.US)$ going down 13.54%… Note to self - investigate why that would have been (strength of trial data? Competitive market for KRAS+ CRC? I.e. not so many people and actually quite a lot of drugs, and OS that’s not so special at 9months)
Evil_Monkey : You have to buy the rumor and sell the news. Once it hits the news, you should have already sold.